‘s-Hertogenbosch, The Netherlands, March 5, 2019 – Bioinformatics software engineering company ENPICOM has closed a series A investment round. BOM Brabant Ventures, Nextgen Ventures and Arches Capital have jointly invested 1.2 million euros to support the company’s repertoire sequencing data analysis platform. ENPICOM will use these proceeds to finalize development of its ImmunoGenomiX (IGX) platform and introduce it in the marketplace.
ENPICOM BV was founded in 2017 by Dr. Alvise Trevisan (CTO), Dr. Nicola Bonzanni (CSO) and Jos Lunenberg, MSc, MBA (CEO). Mid 2017 the company started the development of a unique platform to manage, store, analyze, visualize and interpret clone sequencing data from T and B cell receptor repertoires. ENPICOM is currently in the final stage of preparations for the global launch of the first full version of its ImmunoGenomiX (IGX) platform. This festive event will take place in Vienna at the 6th Immunotherapy of Cancer Conference (ITOC6) from April 11 to 13.
Dr. Bonzanni commented: “When studying immune system related diseases or developing drugs influencing this system, it is extremely important to be able to directly measure and closely monitor its status. Repertoire sequencing is a powerful way to analyze hundreds of thousands to millions of T or B cell receptors swiftly and in a cost-effective way.” “While there are different companies offering kits and service for this specific form of targeted sequencing, there is no commercial platform to manage the rapidly growing amounts of data generated in the lab in an intuitive, user-friendly way,” added Dr. Trevisan. He continued: “To get from data to powerful insights from this exciting technology, smart new analysis methods and rock-solid software were needed. We have built a team of experts, bringing together a wealth of knowledge and expertise in this field, to develop the IGX platform.”
“I am very pleased we have attracted this excellent syndicate of investors. With the completion of this Series A financing, we are well funded to execute on our IGX development and market introduction programs.”
Jos Lunenberg, CEO of ENPICOM
“ENPICOM is a perfect example of what we look for in a portfolio company: a strong, highly skilled, motivated and dedicated team, that is showing the ability to combine innovative emerging technologies like data science, AI and medical science into an exhilarating and fast-growing Deep Tech company, eventually even with a real impact on society. We are very pleased to add ENPICOM to our investment portfolio”.
Eric van der Maten, Managing Partner at Arches Capital
About Arches Capital
Arches Capital, a fast-growing group of business angels, invests in startup and scaleup companies with a large growth potential. Through its investments, Arches Capital bridges the gap between formal investors (VCs) and informal investors (business angels), by joining the best of both worlds:
“ We source, select and invest like a VC;
We engage, care and inspire as the angel we are. ”
By bundling smart capital (combining funding with real business knowledge and experience) with true engagement (actively working together to achieve growth), we are able to ignite early stage companies achieve above-average growth. Arches Capital distinguishes itself from other angel networks by its active support to angels building a broad and professional investment portfolio, co-investment from Arches Capital in each deal and the unique distribution of proceeds amongst its members.
For more information, visit www.arches.capital.
About ENPICOM
ENPICOM is an innovative bioinformatics software engineering company with an outstanding team of professionals. They focus on supporting immunotherapy developers with groundbreaking products and customized solutions to improve and accelerate discovery and development of novel immunotherapies. Clinical validation projects to stratify patients and monitor treatment responses to immunotherapies under development are ongoing.
ENPICOM’s first product on the market is a world-class repertoire sequencing data analysis solution, the ImmunoGenomiX (IGX) platform. IGX is an innovative platform to manage, store, analyze, visualize and interpret clone sequencing data from T and B cell receptor repertoires.
For more information, visit www.enpicom.com.